Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Elangovan Balakrishnan (NPI 1407843022)

Field	Value
Entity Type	Individual
Organization	Elangovan Balakrishnan
Address	1705 E Broadway
City	Columbia
State	MO
ZIP	65201
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	September 29, 2005

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Key Findings

This provider operates squarely within oncology infusion and hematology care: the top revenue drivers are oncology biologics and immunotherapies administered in an infusion setting, reflected by high-volume drug codes such as J9271 and J9299 alongside chemotherapy administration codes (e.g., 96413, 96417). Imaging and diagnostic utilization (A9595, 78815) also appear in the top codes, suggesting the practice coordinates both treatment infusions and cancer-directed diagnostic workups.

Revenue is highly concentrated in a small set of immunotherapy and monoclonal antibody codes: the precomputed top 3 Medicare codes account for 64.3% of this provider's total Medicare revenue, with J9271 producing $1.2M (40.2%), J9299 producing $463.2K (15.3%), and J9144 producing $266.8K (8.8%) of Medicare revenue. This concentration indicates the practice’s financial reliance on a few high-cost oncology agents.

The provider is effectively single-payer from a claims perspective: lifetime Medicare revenue is $3.1M while Medicaid billing is listed as none below, so there is no Medicaid billing on file. That payer mix exposes the provider’s Medicare revenue to payer-specific reimbursement and utilization risk rather than diversification across Medicaid.

Competitive standing across specific drug codes is mixed: for pembrolizumab (J9271) the provider ranks #149 of 1841 nationally (92th percentile) which places it as a relatively prominent national participant for that agent even though the dataset labels the volume as "typical, unremarkable"; for nivolumab (J9299) the provider ranks #177 of 505 (65th percentile) and for daratumumab (J9144) it ranks #362 of 615 (39th percentile), both characterized as typical volumes. These rank/percentile positions show national-level visibility for certain checkpoint inhibitors but more modest presence for other monoclonals.

Several individual codes are statistical outliers or above-typical relative to national peers and highlight operational focus areas: 99214 is labeled an "extreme outlier" (rank #8570 of 479517, 98th percentile) indicating unusually high office E/M volume, J0881 (darbepoetin) is "notably above typical national volume" (rank #40 of 1114, 96th percentile), and chemotherapy administration 96413 is also "notably above typical" (rank #345 of 7514, 95th percentile). Together these labels point to above-average intensity in office evaluation/management and supportive/administrative chemotherapy services compared with peers.

The mix of high-cost immunotherapies (J9271, J9299), supportive biologics and agents (J1568, J2506, J1437, J1439, J0881), and frequent low-paid per-claim injections (J0641 with 30.8K claims at $1 avg paid/claim; J1439 with 22.5K claims at $1 avg paid/claim) suggests an operational model that manages both expensive oncology biologics and high-volume, lower-reimbursement supportive care. This combination implies needs for infusion capacity, drug inventory management, and billing workflows tuned to many small-value claims alongside large biologic charges.

Diagnostic and imaging codes in the top 25 (A9595, 78815, 74177, 71260) indicate the provider either directly orders or bills for cancer-directed imaging and PET/CT diagnostics in support of treatment planning and monitoring; A9595 appears with 99 claims and $48.3K revenue (1.6%) and ranks #475 of 528 (8th percentile), showing use of newer PET tracers at modest volumes. This pattern underscores integrated diagnostic utilization aligned with an oncology service line rather than a purely procedure-focused practice.

This provider is an established presence with a long enumeration history: the NPI was registered on 2005-09-29 (~21 years ago), which supports interpreting current utilization patterns as those of an operational, mature oncology practice rather than a recent entrant.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	28,200	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	19,300	$20	$463.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,020	$40	$266.8K
J0897	Injection, denosumab, 1 mg	12,300	$20	$221.4K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	60,900	$1	$121.8K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	3,420	$30	$116.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,120	$90	$100.7K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,030	$77.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	640	$90	$56.3K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	850	$60	$51.7K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Elangovan Balakrishnan — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	40	9,100	$40	$502K
J9299	5	20	14,170	$20	$360.3K
J9144	13	20	7,200	$40	$308.4K
J1568	2	10	2,900	$30	$103.8K
J0897	17	210	2,400	$20	$82.4K
J0881	2	10	15,500	$1	$63.1K
A9595	2	10	100	$490	$52.7K
J1437	3	10	2,500	$20	$43.5K
Q5116	1	10	1,840	$20	$36.9K
J0641	4	10	35,150	$1	$27.3K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Elangovan Balakrishnan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Liana Makarian	MO	Hematology & Oncology Physician	$3.3M	$0
Umasankar Ramadoss	MO	Hematology & Oncology Physician	$3.3M	$0
Mark Tungesvik	MO	Hematology & Oncology Physician	$3.3M	$0
Andrew Iliff	MO	Hematology & Oncology Physician	$2.8M	$0
Mark Bryer	MO	Radiation Oncology Physician	$638K	$0
Reed Cope	MO	Radiation Oncology Physician	$572.2K	$0
Alexandre Tungesvik	MO	Hematology & Oncology Physician	$569.8K	$0
Harold Johnson	MO	Radiation Oncology Physician	$542.5K	$0
Hunter Nolen	MO	Urology Physician	$359.5K	$0
Andrew Leiker	MO	Radiation Oncology Physician	$303.9K	$0

Nearby Providers

Other providers in the same ZIP code as Elangovan Balakrishnan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Woodhaven	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$88.3M
Palmer's Home Care, LLC	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$82.3M
Oats, Inc.	MO	Non-emergency Medical Transport (VAN)	$0	$23.4M
Independent Living Center Of Mid-missouri Inc.	MO	Specialist	$0	$14.2M
Ch Allied Services, Inc.	MO	General Acute Care Hospital	$0	$8.6M
Central Missouri Area Agency On Aging	MO	Voluntary or Charitable Agency	$0	$8.4M
Life Christain Outreach	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$7.1M
Surgical Center At Columbia Orthopaedic Group LLC	MO	Ambulatory Surgical Clinic/Center	$6.2M	$0
Mid-missouri Supported Living	MO	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$5.3M
Woodhaven Learning Center	MO	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$5.1M

Elangovan Balakrishnan — Billing Profile & Reimbursement Data

Sign up for Elangovan Balakrishnan — Billing Profile & Reimbursement Data policy alerts

Elangovan Balakrishnan — Billing Profile & Reimbursement Data

Sign up for Elangovan Balakrishnan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References